Sökning: WFRF:(Prager Rudolf) > Effect of valsartan...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05075naa a2200913 4500 | |
001 | oai:DiVA.org:umu-50382 | |
003 | SwePub | |
008 | 111207s2010 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-503822 URI |
024 | 7 | a https://doi.org/10.1056/NEJMoa10011212 DOI |
040 | a (SwePub)umu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a McMurray, John J4 aut |
245 | 1 0 | a Effect of valsartan on the incidence of diabetes and cardiovascular events |
264 | 1 | c 2010 |
338 | a print2 rdacarrier | |
520 | a BACKGROUND: It is not known whether drugs that block the renin-angiotensin system reduce the risk of diabetes and cardiovascular events in patients with impaired glucose tolerance. METHODS: In this double-blind, randomized clinical trial with a 2-by-2 factorial design, we assigned 9306 patients with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors to receive valsartan (up to 160 mg daily) or placebo (and nateglinide or placebo) in addition to lifestyle modification. We then followed the patients for a median of 5.0 years for the development of diabetes (6.5 years for vital status). We studied the effects of valsartan on the occurrence of three coprimary outcomes: the development of diabetes; an extended composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, arterial revascularization, or hospitalization for unstable angina; and a core composite outcome that excluded unstable angina and revascularization. RESULTS: The cumulative incidence of diabetes was 33.1% in the valsartan group, as compared with 36.8% in the placebo group (hazard ratio in the valsartan group, 0.86; 95% confidence interval [CI], 0.80 to 0.92; P<0.001). Valsartan, as compared with placebo, did not significantly reduce the incidence of either the extended cardiovascular outcome (14.5% vs. 14.8%; hazard ratio, 0.96; 95% CI, 0.86 to 1.07; P=0.43) or the core cardiovascular outcome (8.1% vs. 8.1%; hazard ratio, 0.99; 95% CI, 0.86 to 1.14; P=0.85). CONCLUSIONS: Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events. (ClinicalTrials.gov number, NCT00097786.) | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
700 | 1 | a Holman, Rury R4 aut |
700 | 1 | a Haffner, Steven M4 aut |
700 | 1 | a Bethel, M Angelyn4 aut |
700 | 1 | a Holzhauer, Björn4 aut |
700 | 1 | a Hua, Tsushung A4 aut |
700 | 1 | a Belenkov, Yuri4 aut |
700 | 1 | a Boolell, Mitradev4 aut |
700 | 1 | a Buse, John B4 aut |
700 | 1 | a Buckley, Brendan M4 aut |
700 | 1 | a Chacra, Antonio R4 aut |
700 | 1 | a Chiang, Fu-Tien4 aut |
700 | 1 | a Charbonnel, Bernard4 aut |
700 | 1 | a Chow, Chun-Chung4 aut |
700 | 1 | a Davies, Melanie J4 aut |
700 | 1 | a Deedwania, Prakash4 aut |
700 | 1 | a Diem, Peter4 aut |
700 | 1 | a Einhorn, Daniel4 aut |
700 | 1 | a Fonseca, Vivian4 aut |
700 | 1 | a Fulcher, Gregory R4 aut |
700 | 1 | a Gaciong, Zbigniew4 aut |
700 | 1 | a Gaztambide, Sonia4 aut |
700 | 1 | a Giles, Thomas4 aut |
700 | 1 | a Horton, Edward4 aut |
700 | 1 | a Ilkova, Hasan4 aut |
700 | 1 | a Jenssen, Trond4 aut |
700 | 1 | a Kahn, Steven E4 aut |
700 | 1 | a Krum, Henry4 aut |
700 | 1 | a Laakso, Markku4 aut |
700 | 1 | a Leiter, Lawrence A4 aut |
700 | 1 | a Levitt, Naomi S4 aut |
700 | 1 | a Mareev, Viacheslav4 aut |
700 | 1 | a Martinez, Felipe4 aut |
700 | 1 | a Masson, Chantal4 aut |
700 | 1 | a Mazzone, Theodore4 aut |
700 | 1 | a Meaney, Eduardo4 aut |
700 | 1 | a Nesto, Richard4 aut |
700 | 1 | a Pan, Changyu4 aut |
700 | 1 | a Prager, Rudolf4 aut |
700 | 1 | a Raptis, Sotirios A4 aut |
700 | 1 | a Rutten, Guy E H M4 aut |
700 | 1 | a Sandström, Herbertu Umeå universitet,Allmänmedicin4 aut0 (Swepub:umu)hesa0015 |
700 | 1 | a Schaper, Frank4 aut |
700 | 1 | a Scheen, Andre4 aut |
700 | 1 | a Schmitz, Ole4 aut |
700 | 1 | a Sinay, Isaac4 aut |
700 | 1 | a Soska, Vladimir4 aut |
700 | 1 | a Stender, Steen4 aut |
700 | 1 | a Tamás, Gyula4 aut |
700 | 1 | a Tognoni, Gianni4 aut |
700 | 1 | a Tuomilehto, Jaako4 aut |
700 | 1 | a Villamil, Alberto S4 aut |
700 | 1 | a Vozár, Juraj4 aut |
700 | 1 | a Califf, Robert M4 aut |
710 | 2 | a Umeå universitetb Allmänmedicin4 org |
773 | 0 | t New England Journal of Medicineg 362:16, s. 1477-1490q 362:16<1477-1490x 0028-4793x 1533-4406 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-50382 |
856 | 4 8 | u https://doi.org/10.1056/NEJMoa1001121 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy